Last reviewed · How we verify
Sodium Citrate 4% Inj Syringe 3Ml — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sodium Citrate 4% Inj Syringe 3Ml (Sodium Citrate 4% Inj Syringe 3Ml) — Johns Hopkins University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sodium Citrate 4% Inj Syringe 3Ml TARGET | Sodium Citrate 4% Inj Syringe 3Ml | Johns Hopkins University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sodium Citrate 4% Inj Syringe 3Ml CI watch — RSS
- Sodium Citrate 4% Inj Syringe 3Ml CI watch — Atom
- Sodium Citrate 4% Inj Syringe 3Ml CI watch — JSON
- Sodium Citrate 4% Inj Syringe 3Ml alone — RSS
Cite this brief
Drug Landscape (2026). Sodium Citrate 4% Inj Syringe 3Ml — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-citrate-4-inj-syringe-3ml. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab